Ironwood Pharma (IRWD) Tops Q3 EPS by 2c; Initiates Phase III Trial of 72 mcg Linaclotide

Ironwood Pharma (NASDAQ: IRWD) reported Q3 EPS of ($0.30), $0.02 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $16.2 million versus the consensus estimate of $21.2 million.

The company also announced today the initiation of a Phase III clinical trial in the U.S. evaluating a 72 mcg capsule of linaclotide to be taken once per day for the treatment of adults suffering from chronic idiopathic constipation (CIC). Linaclotide is currently approved by the U.S. Food and Drug Administration as a 145 mcg capsule to be taken once per day for the treatment of adults with CIC and as a 290 mcg capsule to be taken once per day for the treatment of adults with irritable bowel syndrome with constipation (IBS-C).

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• Jefferies Reinstates Talen Energy (TLN) at Hold